** Shares of Proteomics International Labs rise as much as 8.4% to A$0.71
** The medical technology co says its PromarkerEso blood test for esophageal adenocarcinoma shows 94% accuracy in clinical validation study
** Co says esophageal adenocarcinoma, a cancer arising in the food pipe, is among the leading cause of cancer-related deaths, with a 5-year survival rate of 20%, due to late diagnosis
** Says improved surveillance of at-risk patients using PromarkerEso could enable earlier diagnosis and significantly improve health outcomes
** Stock has fallen 26.8% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.